The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...
PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback